Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RAS mutation
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
RAS mutation
Thyroid Gland Medullary Carcinoma
RAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
cabozantinib capsule
Sensitive
:
A2
cabozantinib capsule
Sensitive: A2 - Guideline
cabozantinib capsule
Sensitive
:
A2
RAS mutation
Acute Myelogenous Leukemia
RAS mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
cetuximab
Resistant: C2 – Inclusion Criteria
cetuximab
Resistant
:
C2
cetuximab
Resistant: C2 – Inclusion Criteria
cetuximab
Resistant
:
C2
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
bevacizumab
Resistant: C2 – Inclusion Criteria
bevacizumab
Resistant
:
C2
bevacizumab
Resistant: C2 – Inclusion Criteria
bevacizumab
Resistant
:
C2
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
regorafenib
Sensitive: C2 – Inclusion Criteria
regorafenib
Sensitive
:
C2
regorafenib
Sensitive: C2 – Inclusion Criteria
regorafenib
Sensitive
:
C2
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
bevacizumab + sintilimab
Sensitive: C2 – Inclusion Criteria
bevacizumab + sintilimab
Sensitive
:
C2
bevacizumab + sintilimab
Sensitive: C2 – Inclusion Criteria
bevacizumab + sintilimab
Sensitive
:
C2
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
binimetinib
Sensitive: C2 – Inclusion Criteria
binimetinib
Sensitive
:
C2
binimetinib
Sensitive: C2 – Inclusion Criteria
binimetinib
Sensitive
:
C2
RAS mutation
Hematological Malignancies
RAS mutation
Hematological Malignancies
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
RAS mutation
Multiple Myeloma
RAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR inhibitor
Sensitive
:
C3
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR inhibitor
Sensitive
:
C3
RAS mutation
Thyroid Gland Anaplastic Carcinoma
RAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
atezolizumab + cobimetinib
Sensitive
:
C3
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
atezolizumab + cobimetinib
Sensitive
:
C3
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
RAS mutation
Thyroid Gland Carcinoma
RAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
RAS mutation
Rectal Cancer
RAS mutation
Rectal Cancer
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
RAS mutation
Rectal Cancer
RAS mutation
Rectal Cancer
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
durvalumab + tremelimumab
Sensitive
:
C3
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
durvalumab + tremelimumab
Sensitive
:
C3
RAS mutation
Acute Myelogenous Leukemia
RAS mutation
Acute Myelogenous Leukemia
mTOR inhibitor
Resistant: D – Preclinical
mTOR inhibitor
Resistant
:
D
mTOR inhibitor
Resistant: D – Preclinical
mTOR inhibitor
Resistant
:
D
RAS mutation
Rhabdomyosarcoma
RAS mutation
Rhabdomyosarcoma
trametinib + AMG 479
Sensitive: D – Preclinical
trametinib + AMG 479
Sensitive
:
D
trametinib + AMG 479
Sensitive: D – Preclinical
trametinib + AMG 479
Sensitive
:
D
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
IMM-6-415
Sensitive: D – Preclinical
IMM-6-415
Sensitive
:
D
IMM-6-415
Sensitive: D – Preclinical
IMM-6-415
Sensitive
:
D
RAS mutation
Pancreatic Ductal Adenocarcinoma
RAS mutation
Pancreatic Ductal Adenocarcinoma
IMM-6-415
Sensitive: D – Preclinical
IMM-6-415
Sensitive
:
D
IMM-6-415
Sensitive: D – Preclinical
IMM-6-415
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login